Azithromycin Three Times a Week Could Prevent COPD Exacerbations

November 2012
AARC Times;Nov2012, Vol. 36 Issue 11, p71
The article reports a study conducted by the Virginia Commonwealth University suggesting routine intake of the antibiotic azithromycin, three times a week would prevent acute exacerbations of chronic obstructive pulmonary disease (COPD).


Related Articles

  • Azithromycin reduces risk of COPD exacerbations.  // Pulse;9/7/2011, Vol. 71 Issue 28, p14 

    The article reports on the result of a new study conducted by U.S. researchers which shows that patients with chronic obstructive pulmonary disease (COPD), who intake azithromycin have lessened the risk of exacerbations.

  • I have chronic obstructive pulmonary disease (COPD) and my doctor is recommending an antibiotic drug long term. Why is this needed?  // Mayo Clinic Health Letter;Dec2015, Vol. 33 Issue 12, p8 

    The article provides an answer to the question of why the doctor recommended an antibiotic drug long term for his chronic obstructive pulmonary disease (COPD).

  • The Effect of Azithromycin in Adults with Stable Neutrophilic COPD: A Double Blind Randomised, Placebo Controlled Trial. Simpson, Jodie L.; Powell, Heather; Baines, Katherine J.; Milne, David; Coxson, Harvey O.; Hansbro, Philip M.; Gibson, Peter G. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive airway disease characterised by neutrophilic airway inflammation or bronchitis. Neutrophilic bronchitis is associated with both bacterial colonisation and lung function decline and is common in exacerbations of COPD....

  • A double-blind, randomised, placebocontrolled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Shafuddin, Eskandarain; Mills, Graham D.; Holmes, Mark D.; Poole, Phillippa J.; Mullins, Peter R.; Black, Peter N. // Journal of Negative Results in Biomedicine;10/9/2015, Vol. 14 Issue 1, p1 

    Background: Azithromycin prophylaxis has been shown to reduce COPD exacerbations but there is poor evidence for other antibiotics. We compared exacerbation rates in COPD patients with a history of frequent exacerbations (at least three moderate or severe COPD exacerbations in the past two years)...

  • Long-Term Azithromycin for Prophylaxis of COPD Exacerbations. Kuritzky, Louis // Primary Care Reports;Nov2011 Clinical Briefs in Primary, p22 

    The article focuses on a study of the effect of long-term azithromycin prophylaxis on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) conducted by R. K. Albert and colleagues and published in a 2011 issue of "The New England Journal of Medicine."

  • Azithromycin does not look cardiotoxic in a general population.  // BMJ: British Medical Journal;5/11/2013, Vol. 346 Issue 7907, p9 

    The article reports a study which found that azithromycin use was not associated with an increased risk of death from cardiovascular causes in a general population of young and middle-aged adults.

  • Azithromycin reduced exacerbations in COPd patients.  // Australian Journal of Pharmacy;May2012, Vol. 93 Issue 1104, p94 

    The article reports on a study conducted to examine effects of azithromycin on exacerbations in patients with chronic obstructive pulmonary disease (COPD). A randomized controlled follow-up study was carried out where individuals were administered aspirin for one year. The results concluded that...

  • TRACHOMA CONTROL. Solomon, Anthony W.; Baltussen, R.; Smith, A.; Chisholm, D. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/14/2012, Vol. 344 Issue 7852, p30 

    A letter to the editor is presented in response to the article "What are the Priorities for Prevention and Control of Non-Communicable Diseases and Injuries in Sub-Saharan Africa and South East Asia," by D. Chisholm and colleagues in the March 2, 2012 issue.

  • Azithromycin: Double-edged Sword in Treatment of Non-CF Bronchiectasis.  // AARC Times;Jul2013, Vol. 37 Issue 7, p139 

    The article discusses a study published in the March 27, 2013 edition of "The Journal of the American Medical Association" about the effectiveness of low-dose macrolide therapy in reducing exacerbation frequency in patients with non-cystic fibrosis bronchiectasis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics